- $45.59m
- $71.25m
- $80.28m
Brief: Tela Bio Q2 Revenue Rose 38 Percent To $10.4 Million
Tela Bio Inc Expected To Post A Loss Of 62 Cents A Share: Earnings Preview
Brief: TELA Bio Highlights Results from Studies on Benefits of OviTex Reinforced Tissue Matrix in Hernia Repairs
Brief: Tela Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement With Premier, Inc.
Brief: Opaleye Management Reports 10.69% Stake In Tela Bio As Of June 7 - SEC Filing
Brief: TELA Bio Secures Up To $50 Million In Debt Financing From Midcap Financial
Tela Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tela Bio Inc Expected To Post A Loss Of 56 Cents A Share: Earnings Preview
Brief: TELA Bio Inc Appoints D. Taylor Ocasio As General Counsel
Tela Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: TELA Bio Reports Fourth Quarter Revenue Of $8.4 Mln
Tela Bio Inc Expected To Post A Loss Of 55cents A Share: Earnings Preview
Brief: Tela Bio Announces U.S. Commercial Launch Of Siteguard™ No Rinse Antimicrobial Solution
Brief: EW Healthcare Partners Fund 2-Ugp Llc Reports 17.13% Stake In Tela Bio Inc As Of January 19
Brief: Tela Bio Appoints Megan Smeykal As Chief Accounting Officer And Principal Accounting Officer
Tela Bio Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Tela Bio Posts Quarterly Loss Per Share Of $0.57
Tela Bio Inc Expected To Post A Loss Of 52 Cents A Share: Earnings Preview
Brief: Tela Bio And Next Science Enter Into Exclusive Distribution Agreement